日本山形县2001–2017年柯萨奇病毒A6分离株的系统发育与抗原性分析
该研究对日本山形县2001–2017年间115株柯萨奇病毒A6(CV-A6)分离株进行VP1及部分VP4-3D区序列和系统发育分析,并使用105份人血清进行抗原性分析。系统发育分析显示CV-A6分离株分为2001–2008年流行株和2010–2017年流行株两个簇。两种兔抗血清对28株山形代表株及原型Gdula株的中和抗体滴度分别为1:2560–1:5120和1:160–1:640,居民血清中和抗体滴度与兔抗血清相似;所有分析株间存在交叉抗原性。
要点
- CV-A6分离株分为2001–2008年和2010–2017年两个遗传簇,新株约2010年传入并替换旧株。
- 针对2001年和2015年山形分离株的兔抗血清中和滴度分别为1:2560–1:5120和1:160–1:640。
- 所有分析CV-A6株间存在交叉抗原性,提示疫苗开发可不受遗传簇限制。
核心结论
- 山形县CV-A6分离株存在两个遗传簇,新株约2010年传入并替换旧株,但所有分析株间存在交叉抗原性。
- 研究提示可通过开发有效诱导针对CV-A6中和抗体的疫苗来预防CV-A6感染,而不受遗传簇限制。
研究设计与样本
- 对日本山形县2001–2017年间115株CV-A6分离株进行VP1和部分VP4-3D区序列及系统发育分析。
- 使用105份人血清进行抗原性分析,并用两种兔抗血清(分别免疫2001年和2015年山形分离株)检测28株山形代表株及原型Gdula株的中和抗体滴度。
主要发现
- 系统发育分析显示CV-A6分离株明显分为两个簇:2001–2008年流行株和2010–2017年流行株。
- 两种兔抗血清对28株山形代表株及原型Gdula株的中和抗体滴度分别为1:2560–1:5120和1:160–1:640。
- 山形居民血清中对上述两株的中和抗体滴度与兔抗血清相似。
- 所有分析CV-A6株间存在交叉抗原性。
临床怎么用
- CV-A6感染的防控可考虑开发能有效诱导中和抗体的疫苗,且疫苗株选择可能无需严格匹配遗传簇。
- 持续开展CV-A6分子流行病学和抗原性监测有助于评估疫苗交叉保护效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although coxsackievirus A6 (CV-A6) is generally recognized as a causative agent of herpangina in children, CV-A6 infections globally emerged as a new and major cause of epidemic hand-foot-and-mouth-diseases (HFMDs) around 2008. To clarify the longitudinal epidemiology of CV-A6, we carried out sequence and phylogenetic analyses for the VP1 and partially for the VP4-3D regions as well as antigenic analysis using 115 CV-A6 isolates and 105 human sera in Yamagata, Japan between 2001 and 2017. Phylogenetic analysis revealed that CV-A6 isolates were clearly divided into two clusters; strains in circulation between 2001 and 2008 and those between 2010 and 2017. Neutralizing antibody titers of two rabbit antisera, which were immunized with Yamagata isolates in 2001 and 2015, respectively, against 28 Yamagata representative strains as well as the prototype Gdula strain were 1:2560-1:5120 and 1:160-1:640, respectively. The neutralizing antibody titers among residents in Yamagata against the above two strains were similar. Our analyses revealed that there were cross-antigenicities among all analyzed CV-A6 strains, although the newly emerged strains were introduced into Yamagata around 2010 and replaced the previous ones. With regard to control measures, these findings suggest that we can prevent CV-A6 infections through the development of a vaccine that effectively induces neutralizing antibodies against CV-A6, irrespective of genetic cluster.
引用
- Mizuta K, Tanaka S, Komabayashi K, et al. Phylogenetic and antigenic analyses of coxsackievirus A6 isolates in Yamagata, Japan between 2001 and 2017. Vaccine. 2019. PMID: 30683510. doi:10.1016/j.vaccine.2018.12.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。